JOINT FILING AGREEMENTJoint Filing Agreement • October 19th, 2022 • Societe Des Produits Nestle S.A. • Medicinal chemicals & botanical products
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
CONFIDENTIALITY AGREEMENTConfidentiality Agreement • September 14th, 2020 • Societe Des Produits Nestle S.A. • Pharmaceutical preparations • Delaware
In connection with the consideration by Société des Produits Nestlé S.A. and its affiliates (“you”) of a possible negotiated strategic transaction (a “Possible Transaction”), with Aimmune Therapeutics, Inc. (“Company”), Company is prepared to make available to you and your Representatives (as hereinafter defined) certain information concerning the business, financial condition, operations, assets and liabilities of Company and its subsidiaries. As a condition to such information being furnished to you and your Representatives, you agree that you will, and will cause your Representatives to, treat the Evaluation Material (as hereinafter defined) in accordance with the provisions of this letter agreement and take or abstain from taking certain other actions as set forth herein. The term “affiliates” has the meaning given to it under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The term “Representatives” shall include directors, officers, employees, attorneys, account
JOINT FILING AGREEMENTJoint Filing Agreement • February 12th, 2021 • Societe Des Produits Nestle S.A. • Biological products, (no disgnostic substances)
The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
JOINT FILING AGREEMENTJoint Filing Agreement • August 31st, 2020 • Societe Des Produits Nestle S.A. • Pharmaceutical preparations
The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned pursuant to Rule 13d-1(k)(1). Société des Produits Nestlé S.A. and Nestlé S.A. acknowledge that each shall be responsible for the timely filing of such Schedule 13D and such amendments, and for the completeness and accuracy of the information concerning it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that it knows or has reason to believe that such information is inaccurate.
JOINT FILING AGREEMENTJoint Filing Agreement • October 13th, 2020 • Societe Des Produits Nestle S.A. • Pharmaceutical preparations
The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of Société des Produits Nestlé S.A. and Nestlé S.A. who are the only remaining reporting persons following this statement on Schedule 13D. Société des Produits Nestlé S.A. and Nestlé S.A. acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.
SUPPLEMENTAL TERMSSupplemental Terms • September 14th, 2020 • Societe Des Produits Nestle S.A. • Pharmaceutical preparations
Further to the Confidentiality Agreement, dated July 25, 2020, between Société des Produits Nestlé S.A. and its affiliates and Aimmune Therapeutics Inc., the parties hereby agree to the supplemental terms set forth in this Supplemental Terms Letter.
Offer to Purchase for Cash All Outstanding Shares of Common Stock ofPurchase Agreement • September 14th, 2020 • Societe Des Produits Nestle S.A. • Pharmaceutical preparations • Delaware
This summary highlights selected information from this Offer to Purchase, the related Letter of Transmittal and other related materials and may not contain all of the information that is important to you. You should carefully read this entire Offer to Purchase, the related Letter of Transmittal and other related materials in their entirety to fully understand the Offer (as defined in this Offer to Purchase), the Merger (as defined in this Offer to Purchase) and the other transactions contemplated by the Merger Agreement (as defined in this Offer to Purchase). References to “we,” “us,” or “our,” unless the context otherwise requires, are references to Purchaser (as defined in this Offer to Purchase). Except as otherwise set forth herein, the information concerning Aimmune (as defined in this Offer to Purchase) contained in this Offer to Purchase has been based upon publicly available documents and records on file with the SEC (as defined in this Offer to Purchase), or other public sourc
